SEC Form 4 · accession 0001493152-26-041135
Ernexa Therapeutics Inc. · ERNA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter Cicala
Director
Period of report
Aug 31, 2026
Accepted (ET)
Sep 1, 2026 · 9:56 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0000748592
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy)F1 | $4.57 | Aug 31, 2026 | A | 5,943 | A | — | Aug 31, 2036 | Common Stock | 5,943 | 5,943 | D |
| Stock Option (Right to buy)F2 | $4.57 | Aug 31, 2026 | A | 5,083 | A | — | Aug 31, 2036 | Common Stock | 5,083 | 5,083 | D |
Explanation of responses
- F1Subject to continued service, one-third of the shares underlying the stock option will vest on the first anniversary of the grant date, and the remaining shares underlying the stock option will vest in 24 substantially equal monthly installments thereafter.
- F2Represents options to purchase shares of the registrant's common stock in lieu of prorated director's cash compensation for 2026 pursuant to the Director's Compensation Plan effective August 15, 2026, granted under the Issuer's 2026 Omnibus Equity Incentive Plan. Subject to continued service, 100% of the stock options will vest on December 31, 2026.